Duopharma Biotech Berhad (Duopharma Biotech) is strengthening its position as a leading pharmaceutical and healthcare company in Malaysia.
It is also a commitment to maintaining its leading position as an innovative pharmaceutical company in the country and a global leader in the halal sector. In addition, its intensified focus on Environmental, Social and Governance (ESG) has made the Group a preferred employer, trusted partner, attractive investment and an increasingly strong brand.
The Group ended 2021 with a stellar five-year record performance, posting revenue of RM639.18 million and a record profit before tax (PBT) of RM82.98 million, amounting to a nine per cent increase from the previous year. Subsequently, the Group started 2022 on a promising note with commendable first quarter 2022 results, as PBT climbed 15 per cent to RM26.65 million, on the back of a 12 per cent higher revenue of RM185.94 million.
At its recent 21st Annual General Meeting (AGM) Duopharma Biotech Chairman Tan Sri Siti Sa’diah Sh Bakir commented: “In 2021, we continued to hold the wellbeing of all employees and stakeholders as our top priority. To keep them safe from Covid-19, we enhanced all pandemic-related standard operating procedures at our plants and maintained split operations at our offices.”
As the global focus on sustainability intensified in recent years, the Group is redoubling its efforts as a responsible corporate citizen by further strengthening its ESG platform. Duopharma Biotech has committed to carbon neutrality by 2030 and net zero emissions by 2050.
In 2021, the Group began developing a five-year ESG Strategy (2022-2026), and in March 2022, Duopharma Biotech announced its environmental pledge in conjunction with its ESG roadmap. The initiatives related to the ESG Strategy will commence this year onwards
Duopharma Biotech Group Managing Director Leonard Ariff Abdul Shatar said: “Looking back, we are pleased that early actions have allowed the Group to navigate the pandemic relatively unscathed. We initiated our emergency response preparations before the pandemic was first declared, and we have managed to maintain a high level of productivity amid the movement restrictions and plant upgrades.”
Leonard Ariff said the Group will focus more on digitalising Duopharma Biotech. As part of the efforts, a Digital Health Strategy has been crafted to identify opportunities that will allow the Group to provide the best solutions along the healthcare value chain.
He added that as part of the plan to expand through multiple avenues, including mergers and acquisitions, the Group has identified and evaluated a number of local and international companies. — The Health